Scarica l'app Stockscreener
175.97
3.35%
5.70
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Insmed Inc Borsa (INSM) Ultime notizie
Insmed (INSM) Stock Undervalued by 54.3% Based on DCF Analysis - Intellectia AI
Is It Too Late To Reassess Insmed (INSM) After Its Huge Share Price Surge? - Yahoo Finance
The Bull Case For Insmed (INSM) Could Change Following Bold 2025 Revenue Guidance HikeLearn Why - Yahoo Finance
What risks investors should watch in Insmed Incorporated stockJuly 2025 Momentum & Low Volatility Stock Suggestions - ulpravda.ru
Tangible book value per share of Insmed Incorporated – BX:IM8N - TradingView — Track All Markets
Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 - Reuters
Insmed (INSM) Surpasses Revenue Expectations with Strong Growth - GuruFocus
Insmed Maps Aggressive 2026: New Lung Disease Drug, Pipeline AdvancesInsmed (NASDAQ:INSM) - Benzinga
Insmed posts early 2025 revenue beating consensus (INSM:NASDAQ) - Seeking Alpha
Insmed: Strong Brinsupri Launch, Solid Arikayce Performance, and 2026 Catalysts Underpin Buy Rating - TipRanks
Insmed jumps after forecasting preliminary 2025 revenue above estimates - TradingView — Track All Markets
Insmed Incorporated Provides Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed shares jump on robust BRINSUPRI rollout and ARIKAYCE outperformance - MSN
Insmed (INSM) Projects Arikayce Revenue of $450M-$470M for FY26 - GuruFocus
INSM Projects Brinsupri Revenue to Reach $172.7 Million by FY25 - GuruFocus
Insmed stock rises after strong BRINSUPRI launch, ARIKAYCE revenue beat By Investing.com - Investing.com UK
Insmed reports strong Q4 revenue for BRINSUPRI and ARIKAYCE By Investing.com - Investing.com UK
Insmed Inc Provides Business Update at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal - Yahoo Finance
Can Insmed Incorporated stock deliver consistent earnings growth2025 Analyst Calls & Short-Term High Return Ideas - ulpravda.ru
Why Insmed Incorporated (IM8N) stock remains top rated2025 Dividend Review & Precise Swing Trade Alerts - ulpravda.ru
Insmed chief legal officer Smith sells $549k in stock By Investing.com - Investing.com Canada
Insmed chief medical officer Flammer sells $2.8m in stock By Investing.com - Investing.com Canada
Insmed chief medical officer Flammer sells $2.8m in stock - Investing.com
Insmed CFO Bonstein sells $808,733 in stock By Investing.com - Investing.com Australia
Insmed COO Adsett sells $747k in stock By Investing.com - Investing.com Canada
Insmed CFO Bonstein sells $808,733 in stock - Investing.com
Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing - MarketScreener
INSMED Chief Legal Officer Sells Shares - TradingView — Track All Markets
Published on: 2026-01-09 00:10:22 - ulpravda.ru
Analysis Recap: Is Insmed Incorporated stock a good choice for value investors2025 Fundamental Recap & AI Powered Market Entry Strategies - ulpravda.ru
Will Insmed Incorporated stock outperform tech sector in 20252025 Market Outlook & Real-Time Stock Price Movement Reports - ulpravda.ru
Will Insmed Incorporated stock recover faster than peersJuly 2025 Summary & Long-Term Investment Growth Plans - ulpravda.ru
Published on: 2026-01-08 19:10:10 - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Jim Cramer on Insmed: "This One Is Worth Keeping an Eye On" - Finviz
Jim Cramer on Insmed: “This One Is Worth Keeping an Eye On” - Insider Monkey
RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating - MarketScreener
Insmed price target raised to $231 from $223 at TD Cowen - MSN
How analysts rate Insmed Incorporated stock todayInterest Rate Changes & Affordable Trading Techniques - ulpravda.ru
Non-Cystic Fibrosis Bronchiectasis Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed - Barchart.com
INSM stock up 78% in 6 months: Here's what you need to know - MSN
What Catalysts Are Quietly Shifting The Narrative For Insmed (INSM)? - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing - marketscreener.com
INSM: UBS Lowers Price Target While Maintaining 'Buy' Rating | I - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating - MarketScreener
Insmed stock price target reiterated at $195 by Leerink on Brinsupri launch - Investing.com UK
INSM Stock Price, Forecast & Analysis | INSMED INC (NASDAQ:INSM) - Chartmill
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Market Review: Why Insmed Incorporated IM8N stock remains top ratedAnalyst Downgrade & High Conviction Investment Ideas - moha.gov.vn
Allspring Global Investments Holdings LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
INSM Stock Up 78% in 6 Months: Here's What You Need to Know - Finviz
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Calamos Advisors LLC Acquires 12,263 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Insmed's chief medical officer sells $2.97 million in stock - MSN
5.47%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):